

[Chem. Pharm. Bull.]  
34(5)1929—1933(1986)

## Potential Bile Acid Metabolites. X. Syntheses of Stereoisomeric 3,7-Dihydroxy-5 $\alpha$ -cholanolic Acids<sup>1)</sup>

TAKASHI IIDA,\*<sup>a</sup> TOSHIKI MOMOSE,<sup>a</sup> TOSHIO NAMBARA,<sup>b</sup>  
and FREDERIC C. CHANG<sup>c</sup>

College of Engineering, Nihon University,<sup>a</sup> Koriyama, Fukushima-ken 963, Japan,  
Pharmaceutical Institute, Tohoku University,<sup>b</sup> Aobayama, Sendai 980, Japan,  
and Department of Chemistry, Harvey Mudd College,<sup>c</sup>  
Claremont, California 91711, U.S.A.

(Received September 17, 1985)

New synthetic routes to allochenodeoxycholic (3 $\alpha$ ,7 $\alpha$ -dihydroxy-5 $\alpha$ -cholanolic) and alloursodeoxycholic (3 $\alpha$ ,7 $\beta$ -dihydroxy-5 $\alpha$ -cholanolic) acids, and their stereoisomers are described. Treatments of allo 7 $\alpha$ -hydroxy-3 $\beta$ -tosyloxy ester with *N,N*-dimethylformamide and of allo 7 $\alpha$ -mesyloxy-3 $\beta$ -tosyloxy and 3 $\beta$ -cathyloxy-7 $\alpha$ -mesyloxy esters with potassium superoxide-crown ether afforded the desired 3 $\alpha$ ,7 $\alpha$ -, 3 $\alpha$ ,7 $\beta$ -, and 3 $\beta$ ,7 $\beta$ -dihydroxy stereoisomers, respectively, in high yield. High-performance liquid chromatography was of key importance in characterizing the compounds and determining their purity.

**Keywords**—bile acid; allo bile acid; 3,7-dihydroxy-5 $\alpha$ -cholanolic acid; allochenodeoxycholic acid; alloursodeoxycholic acid; *N,N*-dimethylformamide reaction; potassium superoxide-18-crown-6 ether reaction; HPLC

Allo (5 $\alpha$ ) cholanolic acids are minor components of the bile of mammals including the human.<sup>2)</sup> As part of a program of synthesis of potential bile acid metabolites, we previously reported the preparation of the four isomers of allo 3,12-dihydroxycholanolic acids.<sup>1)</sup> The present paper describes stereoselective syntheses of the four possible 3,7-dihydroxy allo acids (1—4) via 3-oxo-7 $\alpha$ -hydroxy-4-cholenic acid (5).

7 $\alpha$ -Hydroxy-3-oxo-4-cholenic acids, which would serve as important intermediates in the preparation of the allo bile acids,<sup>3,4)</sup> are accessible by two published procedures.<sup>4,5)</sup> Therefore, we initially applied the precedent methods to the preparation of 5 from chenodeoxycholic acid (6). The first, dehydrogenation with selenium dioxide<sup>4)</sup> of 7 $\alpha$ -hydroxy-3-oxo-5 $\beta$ -cholanolic acid, derived from 6, was found to be impractical because tedious chromatographic purification was required for isolating the desired 5 and only a low yield was obtained. Our attempts to apply the second method recently introduced by Leppik<sup>5)</sup> failed at the dehydrobromination step with lithium carbonate and lithium bromide of 4 $\beta$ -bromo-7 $\alpha$ -formyloxy-3-oxo-5 $\beta$ -cholanolic acid (7), derived from 6, to yield 3-oxo-4,6-choladienic acid as the major product. However, we have been able to obtain the desired 7 $\alpha$ -formyloxy-3-oxo-4-cholenic acid (8) in 42% yield by carrying out the dehydrobromination with the use of semicarbazide and pyruvic acid.<sup>1)</sup> Alkaline hydrolysis of 8 under mild conditions<sup>5)</sup> afforded 5. The overall yield of 5 from 6 was 31%. Treatment of 5 with lithium in liquid ammonia in the presence of methanol as a proton source led to a satisfactory yield (52%) of 3 $\beta$ ,7 $\alpha$ -dihydroxy-5 $\alpha$ -cholanolic acid (3).<sup>4)</sup>

Previous methods for the preparation of allochenodeoxycholic acid (1) involved reduction of the corresponding 3-keto derivative with various agents known to favor axial hydroxy products: a) catalytic hydrogenation in acidic media<sup>6,7)</sup>; b) trimethyl-phosphite and iridium chloride<sup>4)</sup>; and c) K-Selectride (potassium *tri-sec*-butylborohydride).<sup>8)</sup> However, with all these procedures, 1a (as the ester) had to be isolated by chromatographic separation from

the resulting mixture of epimers and other by-products. Therefore, we performed the synthesis of **1a** by inversion of an equatorial hydroxyl group at C-3, the method described in a previous paper.<sup>9</sup> The 3 $\beta$ -hydroxy ester (**3a**) readily yielded the 3 $\beta$ -monotosylate (**9a**), which underwent inversion with *N,N*-dimethylformamide (DMF) to give **1a** in good yield (82%). This product was easily hydrolyzable to the acid (**1**).

Alloursodeoxycholic acid (**2**) has previously been prepared from methyl 3 $\alpha$ -carboethoxy-6-bromo-7,12-diketo-5 $\beta$ -cholanate.<sup>10</sup> Our new synthesis is an application of a direct stereospecific reaction discovered in the 5 $\beta$ -series.<sup>11-13</sup> 7 $\alpha$ -Mesyloxy-3 $\beta$ -tosyloxy ester (**10a**), when subjected to treatment with potassium superoxide (KO<sub>2</sub>)-18-crown-6 ether in dimethyl sulfoxide (DMSO), underwent simultaneous inversion at both C-3 and C-7, accompanied by hydrolysis of the C-24 ester group to give **2** in 59% isolated yield. In the 5 $\beta$ -series, the 3 $\alpha$ -tosyloxy group required 22 h for complete inversion in the KO<sub>2</sub>-crown ether reaction.<sup>12,13</sup> In contrast, under identical conditions, the equatorial 3 $\beta$ -tosylate in the 5 $\alpha$ -series underwent complete inversion in 8 h.




Chart 1

TABLE I. TLC and HPLC Data for 3,7-Dihydroxy Stereoisomers of Bile Acid Esters<sup>a)</sup>

Configuration of hydroxyls	TLC <sup>b)</sup> ( <i>R<sub>f</sub></i> -Values)		HPLC <sup>c)</sup> ( <i>k'</i> -Values)	
	5 $\alpha$	5 $\beta$	5 $\alpha$	5 $\beta$
3 $\alpha$ ,7 $\alpha$	0.21	0.27	1.13	1.00
3 $\alpha$ ,7 $\beta$	0.25	0.23	0.36	0.31
3 $\beta$ ,7 $\alpha$	0.18	0.30	0.44	0.51
3 $\beta$ ,7 $\beta$	0.17	0.23	0.39	0.34

<sup>a)</sup> The designation 5 $\alpha$  refers to allocholanates, and 5 $\beta$  to 5 $\beta$ -cholanates. <sup>b)</sup> In TLC on silica gel, the samples were analyzed as the C-24 methyl esters and developed in hexane-EtOAc-acetic acid (50:50:1, v/v/v). <sup>c)</sup> The samples were analyzed as the C-24 4-nitrophthalimidemethyl esters under the following conditions: column, Nova-Pak C<sub>18</sub>; detector, UV at 254 nm; mobile phase, MeOH-water (75:25, v/v); flow rate, 0.7 ml/min. Capacity factors (*k'*) were expressed relative to that of 3 $\alpha$ ,7 $\alpha$ -dihydroxy-5 $\beta$ -cholic acid ester.

The fourth 3 $\beta$ ,7 $\beta$ -dihydroxy stereoisomer (**4**) had previously been isolated as the ester by the Raney nickel reduction of methyl 6-oxo-3 $\alpha$ ,7 $\beta$ -dihydroxy-5 $\alpha$ -cholanate 6,6-ethylene-thioketal.<sup>14,15</sup> The present synthesis is analogous to the conversion of **10a** to **2**. The 3 $\beta$ -

cathyloxy-7 $\alpha$ -mesyloxy ester (**12a**), derived from the 3 $\beta$ -cathyloxy-7 $\alpha$ -hydroxy ester (**11a**), was directly converted by means of the KO<sub>2</sub>-crown ether reaction to **4** in excellent yield (77%).

Table I shows the *R<sub>f</sub>*-values on thin layer chromatography (TLC) and the *k'<sub>r</sub>*-values (relative capacity factors) on high-performance liquid chromatography (HPLC) for the C-24 esters of stereoisomeric 3,7-dihydroxy-5 $\alpha$ -cholanolic acids, together with the data for the corresponding esters of the 5 $\beta$ -series.<sup>12)</sup> The *R<sub>f</sub>*- and *k'<sub>r</sub>*-values were obtained for the methyl and 4-nitrophthalimidemethyl<sup>16)</sup> esters, respectively. As can be seen, two of the allo 3,7-diol isomers and some isomeric pairs of the 5 $\alpha$ - and 5 $\beta$ -series exhibit very similar mobilities on TLC. However, all eight 3,7-dihydroxy stereoisomers were well resolved by HPLC on a C<sub>18</sub> reversed-phase column. It should be noted that the 3 $\alpha$ ,7 $\alpha$ -diols of both the 5 $\alpha$ - and 5 $\beta$ -series are eluted much more slowly than the others.

### Experimental

Melting points were determined on a micro hot stage apparatus and are uncorrected. Infrared (IR) spectra were obtained on a JASCO IRA-II double beam spectrometer as KBr tablets. Ultraviolet (UV) spectra were determined in ethanol solution using a Shimadzu UV-200 double-beam spectrophotometer. Proton nuclear magnetic resonance (<sup>1</sup>H-NMR) spectra were obtained on a JEOL FX-90Q instrument with CDCl<sub>3</sub> containing 1% Me<sub>4</sub>Si as the solvent except where otherwise indicated; chemical shifts are expressed in  $\delta$  (ppm) relative to Me<sub>4</sub>Si. Mass spectra (MS) were recorded on a Hitachi RMU-7M mass spectrometer under the following conditions: ion source temperature, 180 °C; ionizing voltage, 70 eV. HPLC was carried out on a Waters Associates system (M-45 pump; U6K sample loop injector; R401 differential refractometer or Shimadzu SPD-2A UV detector) using a Nova-Pak C<sub>18</sub> reversed-phase column (15 cm  $\times$  3.9 mm i.d., 5  $\mu$ m; Waters Associates) with MeOH-water mixture (75:25, v/v) as the mobile phase. Analytical TLC was performed on pre-coated silica gel (20 cm  $\times$  20 cm, 0.25 mm layer thickness; E. Merck AG) using hexane-EtOAc-acetic acid mixture (50:50:1, v/v/v) as the developing solvent for methyl esters.

**4 $\beta$ -Bromo-7 $\alpha$ -formyloxy-3-oxo-5 $\beta$ -cholanolic Acid (7)**—Prepared from 7 $\alpha$ -formyloxy-3-oxo-5 $\alpha$ -cholanolic acid (**13**) (obtained from **6**)<sup>17)</sup> by the bromination procedure described in the previous paper.<sup>1)</sup> Crystallization of the oily product from EtOAc-hexane gave **7** as colorless needles. mp 159–161 °C. IR  $\nu_{\max}$  cm<sup>-1</sup>: 1720, 1708 (C=O), 1178 (C–O), 560 (C–Br). <sup>1</sup>H-NMR  $\delta$ : 0.70 (3H, s, 18-H), 0.94 (3H, d, *J* = 5.4 Hz, 21-H), 1.10 (3H, s, 19-H), 5.17 (1H, m, 7-H), 5.33 (1H, d, *J* = 11.7 Hz, 4-H), 8.08 (1H, s, CHO). *Anal.* Calcd for C<sub>25</sub>H<sub>37</sub>BrO<sub>5</sub>: C, 60.36; H, 7.50. Found: C, 59.93; H, 7.65.

**7 $\alpha$ -Formyloxy-3-oxo-4-cholenic Acid (8)**—A solution of semicarbazide (2.6 g) and sodium acetate (1.7 g) in water (10 ml) was added to a solution of **7** (4.4 g) in acetic acid (150 ml). The mixture was stirred for 30 min at 60 °C under N<sub>2</sub> and then for 1 h at room temperature. Water was added gradually to the mixture to cause precipitation of the semicarbazone of **8**, which was filtered off and washed with water. A solution of pyruvic acid (9 ml) in water (22 ml) was added to a solution of the crude semicarbazone in acetic acid (90 ml). The mixture was stirred overnight at room temperature under N<sub>2</sub>, and the precipitated solid was filtered off. The filtrate was extracted with EtOAc three times, and the combined extracts were washed with water to neutrality, dried over Drierite, and evaporated. The pale yellow residue (2.69 g) was chromatographed on a column of silica gel (120 g). Elution with benzene-EtOAc (9:1, v/v) gave 0.82 g (25%) of a solid which was characterized as 3-oxo-4,6-choladienic acid. mp 197–198 °C (CH<sub>2</sub>Cl<sub>2</sub>-hexane). IR  $\nu_{\max}$  cm<sup>-1</sup>: 1710 (C=O), 1628, 1608 (4,6-diene). UV  $\lambda_{\max}$  nm ( $\epsilon$ ): 284 (30500). <sup>1</sup>H-NMR  $\delta$ : 0.77 (3H, s, 18-H), 0.95 (3H, d, *J* = 5.4 Hz, 21-H), 1.11 (3H, s, 19-H), 5.69 (1H, s, 4-H), 6.12 (2H, s, 6- and 7-H). *Anal.* Calcd for C<sub>24</sub>H<sub>34</sub>O<sub>3</sub>: C, 77.80; H, 9.25. Found: C, 77.97; H, 9.18.

Further elution with benzene-EtOAc (7:3, v/v) and crystallization of the eluate from acetone-hexane gave **8** (1.53 g; 42%) as colorless fine needles. mp 199–200 °C. IR  $\nu_{\max}$  cm<sup>-1</sup>: 1730 (C=O), 1650 (4-ene), 1180, 1160 (C–O). UV  $\lambda_{\max}$  nm ( $\epsilon$ ): 248 (17000). <sup>1</sup>H-NMR  $\delta$ : 0.72 (3H, s, 18-H), 0.94 (3H, d, *J* = 5.4 Hz, 21-H), 1.22 (3H, s, 19-H), 5.16 (1H, m, 7-H), 5.70 (1H, s, 4-H), 8.05 (1H, s, CHO). *Anal.* Calcd for C<sub>25</sub>H<sub>36</sub>O<sub>5</sub>: C, 72.08; H, 8.71. Found: C, 71.91; H, 8.63.

**3-Oxo-7 $\alpha$ -hydroxy-4-cholenic Acid (5)**—Prepared from **8** by a slight modification of the procedure of Leppik.<sup>5)</sup> Recrystallization from aq. MeOH gave **5** (94%) as colorless fine needles. mp 227–229 °C (lit. mp 231–233 °C).<sup>4)</sup> IR  $\nu_{\max}$  cm<sup>-1</sup>: 1718 (C=O), 1630 (4-ene), 3500 (OH). UV  $\lambda_{\max}$  nm ( $\epsilon$ ): 242 (15900). <sup>1</sup>H-NMR (CDCl<sub>3</sub> + 20% DMSO-*d*<sub>6</sub>)  $\delta$ : 0.71 (3H, s, 18-H), 0.93 (3H, d, *J* = 5.4 Hz, 21-H), 1.19 (3H, s, 19-H), 3.91 (1H, m, 7-H), 5.70 (1H, s, 4-H).

**Methyl 3 $\beta$ ,7 $\alpha$ -Dihydroxy-5 $\alpha$ -cholanate (3a)**—The acid (**5**) was reduced with Li-NH<sub>3</sub><sup>4)</sup> and the reaction was quenched by adding MeOH. Treatment of the residual bile salts by acidification followed by methyl esterification, and chromatographic purification of the product, gave **3a** as the main product (52%). mp 160–161 °C (acetone-hexane) (lit. mp 159–160 °C<sup>4)</sup> and 160–161 °C<sup>7)</sup>). IR  $\nu_{\max}$  cm<sup>-1</sup>: 1713 (C=O), 3530, 1033, 1015 (OH). <sup>1</sup>H-NMR  $\delta$ : 0.66 (3H, s, 18-H), 0.80 (3H, s, 19-H), 0.92 (3H, d, *J* = 6.3 Hz, 21-H), 3.58 (1H, br m, 3-H), 3.66 (3H, s, COOMe), 3.84

(1H, m, 7-H). MS  $m/z$  (relative intensity): 406 (2,  $M^+$ ), 388 (100,  $M-H_2O$ ), 373 (25,  $M-H_2O-CH_3$ ), 273 [83,  $M-H_2O$ -side chain (SC)], 264 (20,  $M-SC$ -part of ring D), 249 (38,  $M-SC$ -ring D), 246 (46,  $M-H_2O$ -part of ring D).

**3 $\beta$ ,7 $\alpha$ -Dihydroxy-5 $\alpha$ -cholanolic Acid (3)**—Prepared from 3a by the usual method with 5% methanolic KOH. Recrystallization of the product from aq. MeOH gave 3 as colorless needles. mp 271–272 °C (lit. mp 273–274.5 °C).<sup>2)</sup> IR  $\nu_{max}$   $cm^{-1}$ : 1715 (C=O), 3550, 1042, 1024 (OH). <sup>1</sup>H-NMR ( $CDCl_3 + 20\%$  DMSO- $d_6$ )  $\delta$ : 0.65 (3H, s, 18-H), 0.78 (3H, s, 19-H), 0.92 (3H, d,  $J=5.4$  Hz, 21-H), 3.53 (1H, br m, 3-H), 3.74 (1H, m, 7-H).

**Methyl 7 $\alpha$ -Hydroxy-3 $\beta$ -tosyloxy-5 $\alpha$ -cholanate (9a)**—Prepared from 3a by the tosyl chloride-pyridine method<sup>18)</sup> in quantitative yield. Crystallization from benzene-hexane gave 9a as colorless prisms. mp 157–158 °C. IR  $\nu_{max}$   $cm^{-1}$ : 1733 (C=O), 1333, 1175, 920, 868 ( $SO_2$ ), 3600, 1032, 1016 (OH). <sup>1</sup>H-NMR  $\delta$ : 0.64 (3H, s, 18-H), 0.77 (3H, s, 19-H), 0.90 (3H, d,  $J=5.4$  Hz, 21-H), 2.44 (3H, s, ArMe), 3.65 (3H, s, COOMe), 3.79 (1H, m, 7-H), 4.39 (1H, br m, 3-H), 7.32 and 7.78 (each 2H, d,  $J=9.0$  Hz, *para*-disubstituted phenyl). Anal. Calcd for  $C_{32}H_{48}O_6S$ : C, 68.54; H, 8.63. Found: C, 68.78; H, 8.36.

**Methyl 3 $\alpha$ ,7 $\alpha$ -Dihydroxy-5 $\alpha$ -cholanate (1a)**—A solution of 9a (320 mg) in DMF (15 ml) was kept at  $80 \pm 1$  °C for 65 h. The reaction mixture was diluted with water and the product was extracted with  $CH_2Cl_2$ . The  $CH_2Cl_2$  extract was washed with water, dried over Drierite and evaporated. The residual oily product was dissolved in benzene and poured onto a column of neutral alumina (activity II, ratio 50 : 1). After 18 h, the column was eluted with benzene-EtOAc (1 : 1, v/v) and recrystallization of the eluate from aq. acetone gave 1a (190 mg; 82%) as colorless thin plates. mp 126.5–127.5 °C (lit. mp 116–118 °C<sup>4)</sup> and 125–126 °C<sup>6)</sup>). IR  $\nu_{max}$   $cm^{-1}$ : 1735, 1713 (C=O), 3380, 1033 (OH). <sup>1</sup>H-NMR  $\delta$ : 0.66 (3H, s, 18-H), 0.78 (3H, s, 19-H), 0.93 (3H, d,  $J=6.3$  Hz, 21-H), 3.66 (3H, s, COOMe), 3.83 (1H, m, 7-H), 4.05 (1H, m, 3-H). MS  $m/z$  (relative intensity): 406 (4,  $M^+$ ), 388 (100,  $M-H_2O$ ), 373 (27,  $M-H_2O-CH_3$ ), 370 (25,  $M-2H_2O$ ), 355 (17,  $M-2H_2O-CH_3$ ), 273 (93,  $M-H_2O-SC$ ), 264 (24,  $M-SC$ -part of ring D), 249 (38,  $M-SC$ -ring D), 246 (42,  $M-H_2O-SC$ -part of ring D).

**3 $\alpha$ ,7 $\alpha$ -Dihydroxy-5 $\alpha$ -cholanolic Acid (1)**—Prepared from 1a by the usual hydrolysis procedure. Recrystallization of the product from EtOAc gave 1 as colorless needles. mp 245–247 °C (lit. mp 245–246 °C<sup>7)</sup> and 238–240 °C<sup>19)</sup>). IR  $\nu_{max}$   $cm^{-1}$ : 1700 (C=O), 3400, 1027, 1000 (OH). <sup>1</sup>H-NMR ( $CDCl_3 + 20\%$  DMSO- $d_6$ )  $\delta$ : 0.64 (3H, s, 18-H), 0.75 (3H, s, 19-H), 0.91 (3H, d,  $J=5.4$  Hz, 21-H), 3.72 (1H, m, 7-H), 3.95 (1H, m, 3-H).

**Methyl 7 $\alpha$ -Mesyloxy-3 $\beta$ -tosyloxy-5 $\alpha$ -cholanate (10a)**—Methanesulfonyl chloride (0.8 ml) was slowly added dropwise to a stirred solution of 9a (700 mg) in dry pyridine (10 ml). Stirring was continued for 1 h and the mixture was then allowed to stand overnight at room temperature. The dark brown solution was dripped into cold water and extracted with  $CH_2Cl_2$ . The  $CH_2Cl_2$  extract was washed successively with water, 3N HCl, and water, decolorized with Norite, and evaporated. The residual oil (740 mg), although apparently homogeneous on TLC and <sup>1</sup>H-NMR analyses, could not be crystallized. IR  $\nu_{max}$   $cm^{-1}$ : 1732 (C=O), 1350, 1177 ( $SO_2$ ), 930, 892, 863 (mesylate). <sup>1</sup>H-NMR  $\delta$ : 0.64 (3H, s, 18-H), 0.80 (3H, s, 19-H), 0.90 (3H, d,  $J=6.3$  Hz, 21-H), 2.43 (3H, s, ArMe), 3.00 (3H, s,  $SO_2Me$ ), 3.65 (3H, s, COOMe), 4.39 (1H, br m, 3-H), 4.80 (1H, m, 7-H), 7.30 and 7.76 (each 2H, d,  $J=8.1$  Hz, *para*-disubstituted phenyl). Anal. Calcd for  $C_{33}H_{50}O_8S_2$ : C, 62.05; H, 7.89. Found: C, 61.96; H, 7.63.

**3 $\alpha$ ,7 $\beta$ -Dihydroxy-5 $\alpha$ -cholanolic Acid (2)**—A suspension of powdered  $KO_2$  (160 mg) in dry DMSO (12 ml) was stirred under  $N_2$  for 10 min, then 18-crown-6 (90 mg) was added. The suspension was further stirred at room temperature until most of the  $KO_2$  was dissolved (*ca.* 2 h). A solution of 10a (320 mg) dissolved in DMSO (5 ml) was then added to the above solution and the mixture was stirred under  $N_2$  for an additional 8 h. The flask was immersed in an ice bath, and saturated NaCl solution (15 ml) was added gradually. The resulting solution was extracted with benzene. The aq. layer was cooled in an ice bath, acidified with 3N HCl, and extracted with EtOAc. The EtOAc extract was washed with water, dried over Drierite, and evaporated to dryness. The residue, when treated with aq. MeOH, afforded 115 mg (59%) of 2 as colorless needles. mp 243.5–245.0 °C (lit. mp 223–224 °C).<sup>10)</sup> IR  $\nu_{max}$   $cm^{-1}$ : 1677 (C=O), 3300, 1032, 1003 (OH). <sup>1</sup>H-NMR ( $CDCl_3 + 20\%$  DMSO- $d_6$ )  $\delta$ : 0.68 (3H, s, 18-H), 0.78 (3H, s, 19-H), 0.93 (3H, d,  $J=5.4$  Hz, 21-H), 3.40 (1H, br m, 7-H), 3.95 (1H, m, 3-H).

**Methyl 3 $\alpha$ ,7 $\beta$ -Dihydroxy-5 $\alpha$ -cholanate (2a)**—Prepared from 2 by the usual esterification method. The ester, although apparently homogeneous on TLC and <sup>1</sup>H-NMR analyses, could not be crystallized. IR  $\nu_{max}^{CH_2Cl_2}$   $cm^{-1}$ : 1735 (C=O), 3430, 1032, 1003 (OH). <sup>1</sup>H-NMR  $\delta$ : 0.68 (3H, s, 18-H), 0.79 (3H, s, 19-H), 0.93 (3H, d,  $J=5.4$  Hz, 21-H), 3.34 (1H, br m, 7-H), 3.65 (3H, s, COOMe), 4.05 (1H, m, 3-H). MS  $m/z$  (relative intensity): 388 (64,  $M-H_2O$ ), 373 (14,  $M-H_2O-CH_3$ ), 370 (100,  $M-2H_2O$ ), 355 (36,  $M-2H_2O-CH_3$ ), 255 (64,  $M-2H_2O-SC$ ), 249 (25,  $M-SC$ -ring D), 246 (22,  $M-H_2O-SC$ -part of ring D). Anal. Calcd for  $C_{25}H_{42}O_4$ : C, 73.85; H, 10.41. Found: C, 73.58; H, 10.32.

**Methyl 3 $\beta$ -Cathyloxy-7 $\alpha$ -hydroxy-5 $\alpha$ -cholanate (11a)**—Prepared from 3a (700 mg) by the cathylation method reported previously.<sup>11)</sup> Crystallization from acetone-hexane gave 11a (610 mg; 74%) as colorless needles. mp 120–121 °C (lit. mp 122–123 °C).<sup>15)</sup> IR  $\nu_{max}$   $cm^{-1}$ : 1738 (C=O), 3560 (OH). <sup>1</sup>H-NMR  $\delta$ : 0.66 (3H, s, 18-H), 0.81 (3H, s, 19-H), 0.91 (3H, d,  $J=6.3$  Hz, 21-H), 1.30 (3H, t,  $J=7.2$  Hz,  $OCOCH_2CH_3$ ), 3.65 (3H, s, COOMe), 3.80 (1H, m, 7-H), 4.15 (2H, q,  $J=6.3$  Hz,  $OCOCH_2CH_3$ ), 4.59 (1H, br m, 3-H).

**Methyl 3 $\beta$ -Cathyloxy-7 $\alpha$ -mesyloxy-5 $\alpha$ -cholanate (12a)**—Prepared from 11a (500 mg) by the mesylation procedure described above. The oily product (530 mg), although apparently homogeneous on TLC and <sup>1</sup>H-NMR

analyses, could not be crystallized. IR  $\nu_{\max}$   $\text{cm}^{-1}$ : 1735 (C=O), 1332, 1175 ( $\text{SO}_2$ ), 890 (mesylate).  $^1\text{H-NMR}$   $\delta$ : 0.66 (3H, s, 18-H), 0.84 (3H, s, 19-H), 0.92 (3H, d,  $J=5.4$  Hz, 21-H), 1.30 (3H, t,  $J=7.2$  Hz,  $\text{OCOCH}_2\text{CH}_3$ ), 3.02 (3H, s,  $\text{SO}_2\text{Me}$ ), 3.66 (3H, s, COOMe), 4.17 (2H, q,  $J=6.3$  Hz,  $\text{OCOCH}_2\text{CH}_3$ ), 4.60 (1H, br m, 3-H), 4.90 (1H, m, 7-H). *Anal.* Calcd for  $\text{C}_{29}\text{H}_{48}\text{O}_8\text{S}$ : C, 62.57; H, 8.69. Found: C, 62.38; H, 8.85.

**3 $\beta$ ,7 $\beta$ -Dihydroxy-5 $\alpha$ -cholanolic Acid (4)**—The ester (12a) (280 mg), subjected to the  $\text{KO}_2$ -18-crown-6 ether inversion procedure as described above, required 1.5 h for complete reaction. The mixture was processed, and the resulting product was crystallized from aq. MeOH to give 4 (152 mg; 77%) as colorless crystals. mp 245.0–246.5 °C (lit. mp 240–241 °C).<sup>2)</sup> IR  $\nu_{\max}$   $\text{cm}^{-1}$ : 1690 (C=O), 3400, 1034 (OH),  $^1\text{H-NMR}$  ( $\text{CDCl}_3 + 20\%$  DMSO- $d_6$ )  $\delta$ : 0.67 (3H, s, 18-H), 0.91 (3H, s, 19-H), 0.93 (3H, d,  $J=6.3$  Hz, 21-H), 3.35 (2H, br m, 3- and 7-H).

**Methyl 3 $\beta$ ,7 $\beta$ -Dihydroxy-5 $\alpha$ -cholanate (4a)**—Prepared from 4 by the usual esterification procedure. Crystallization from EtOAc gave 4a as colorless needles. mp 159–160 °C (lit. mp 158–159 °C).<sup>15)</sup> IR  $\nu_{\max}$   $\text{cm}^{-1}$ : 1735 (C=O), 3340, 1037 (OH).  $^1\text{H-NMR}$   $\delta$ : 0.69 (3H, s, 18-H), 0.83 (3H, s, 19-H), 0.93 (3H, d,  $J=6.3$  Hz, 21-H), 3.41 (2H, br m, 3- and 7-H), 3.66 (3H, s, COOMe). MS  $m/z$  (relative intensity): 406 (2,  $\text{M}^+$ ), 388 (100,  $\text{M}-\text{H}_2\text{O}$ ), 373 (35,  $\text{M}-\text{H}_2\text{O}-\text{CH}_3$ ), 273 (62,  $\text{M}-\text{H}_2\text{O}-\text{SC}$ ), 264 (20,  $\text{M}-\text{SC}$ —part of ring D), 255 (27,  $\text{M}-2\text{H}_2\text{O}-\text{SC}$ ), 249 (29,  $\text{M}-\text{SC}$ —ring D), 246 (35,  $\text{M}-\text{H}_2\text{O}-\text{SC}$ —part of ring D).

**Acknowledgement** This work was supported in part by a grant from the Japan Association of Chemistry (to T. Iida). We thank the Department of Pharmacy, College of Science and Technology, Nihon University, for IR, MS, and elemental analyses.

#### References and Notes

- 1) Part IX of this series: T. Iida, T. Tamura, T. Matsumoto, and F. C. Chang, *J. Lipid Res.*, **26**, 874 (1985). In conformity with the nomenclature of the previous papers of this series, the older name "cholanolic" acid is used in plane of the newer IUPAC-recommended "cholanoic" acid. The corresponding methyl esters are designated "a" after the compound number. The following trivial names are used in this paper: allochenodeoxycholic acid = 3 $\alpha$ ,7 $\alpha$ -dihydroxy-5 $\alpha$ -cholanolic acid; alloursodeoxycholic acid = 3 $\alpha$ ,7 $\beta$ -dihydroxy-5 $\alpha$ -cholanolic acid; chenodeoxycholic acid = 3 $\alpha$ ,7 $\alpha$ -dihydroxy-5 $\beta$ -cholanolic acid.
- 2) W. H. Elliott, "The Bile Acids," Vol. 1 (Chemistry), ed. by P. P. Nair and D. Krichevsky, Plenum Press, New York, 1971, p. 47.
- 3) C. C. Beard, "Organic Reactions in Steroid Chemistry," Vol. 1, ed. by J. Fried and J. A. Edwards, Van Nostrand Reinhold Co., New York, 1972, p. 265.
- 4) A. Kallner, *Acta Chem. Scand.*, **21**, 322 (1967).
- 5) R. A. Leppik, *Steroids*, **41**, 475 (1983).
- 6) S. A. Ziller, Jr., M. N. Mitra, and W. H. Elliott, *Chem. Ind. (London)*, **1967**, 999.
- 7) S. A. Ziller, Jr., E. A. Doisy, Jr., and W. H. Elliott, *J. Biol. Chem.*, **243**, 5280 (1968).
- 8) D. M. Tal, G. D. Frisch, and W. H. Elliott, *Tetrahedron*, **40**, 851 (1984).
- 9) F. C. Chang and R. T. Blickenstaff, *J. Am. Chem. Soc.*, **80**, 2906 (1958).
- 10) T. Goto, *Proc. Jpn. Acad.*, **31**, 466 (1955).
- 11) T. Iida, H. R. Taneja, and F. C. Chang, *Lipids*, **16**, 863 (1981).
- 12) T. Iida and F. C. Chang, *J. Org. Chem.*, **47**, 2966 (1982).
- 13) T. Iida and F. C. Chang, *J. Org. Chem.*, **47**, 2972 (1982).
- 14) I. G. Anderson and G. A. D. Haslewood, *Biochem. J.*, **85**, 236 (1962).
- 15) S. A. Ziller, Jr., P. A. Houser, and W. H. Elliott, *Steroids*, **23**, 221 (1974).
- 16) T. Iida, Y. Ohnuki, F. C. Chang, J. Goto, and T. Nambara, *Lipids*, **20**, 187 (1985).
- 17) K-Y. Tserng and P. D. Klein, *Steroids*, **29**, 635 (1977).
- 18) F. C. Chang, R. T. Blickenstaff, A. Feldstein, J. R. Gray, G. S. McCaleb, and D. H. Sprunt, *J. Am. Chem. Soc.*, **79**, 2164 (1957).
- 19) T. Hoshita, K. Amimoto, T. Nakagawa, and T. Kazuno, *J. Biochem. (Tokyo)*, **61**, 750 (1967).